Your browser doesn't support javascript.
loading
Targeting the Endothelin A Receptor in IgA Nephropathy.
Kohan, Donald E; Barratt, Jonathan; Heerspink, Hiddo J L; Campbell, Kirk N; Camargo, Mariannne; Ogbaa, Ike; Haile-Meskale, Ruth; Rizk, Dana V; King, Andrew.
Affiliation
  • Kohan DE; Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.
  • Barratt J; Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
  • Campbell KN; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Camargo M; Chinook Therapeutics, Seattle, Washington, USA.
  • Ogbaa I; Chinook Therapeutics, Seattle, Washington, USA.
  • Haile-Meskale R; Chinook Therapeutics, Seattle, Washington, USA.
  • Rizk DV; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • King A; Chinook Therapeutics, Seattle, Washington, USA.
Kidney Int Rep ; 8(11): 2198-2210, 2023 Nov.
Article in En | MEDLINE | ID: mdl-38025243
ABSTRACT
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and carries a substantial risk of kidney failure. New agency-approved therapies, either specifically for IgAN or for chronic kidney disease (CKD) in general, hold out hope for mitigating renal deterioration in patients with IgAN. The latest addition to this therapeutic armamentarium targets the endothelin-A receptor (ETAR). Activation of ETAR on multiple renal cell types elicits a host of pathophysiological effects, including vasoconstriction, cell proliferation, inflammation, apoptosis, and fibrosis. Blockade of ETAR is renoprotective in experimental models of IgAN and reduces proteinuria in patients with IgAN. This review discusses the evidence supporting the use of ETAR blockade in IgAN as well as addressing the potential role for this class of agents among the current and emerging therapies for treating this disorder.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Kidney Int Rep Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Kidney Int Rep Year: 2023 Type: Article Affiliation country: United States